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AimsWe compared the prevalence and prognostic implications of non-sustained ventricular tachycardia
(nsVT) detected early after ST-segment elevation myocardial infarction (STEMI) in patients randomized
to either ﬁbrinolysis or primary angioplasty in the DANAMI-2 trial.
Methods and results Holter recordings were available in 1017 patients (ﬁbrinolysis: n ¼ 501; primary
angioplasty: n ¼ 516). Primary endpoint was all-cause mortality. The prevalence of nsVT was 8.8% in
ﬁbrinolysis-treated, and 8.1% in primary angioplasty-treated patients (P ¼ 0.71). During 4519 patient-
years of follow-up (median 4.3 years), 116 patients died [ﬁbrinolysis vs. angioplasty: HR ¼ 1.1 (95%
CI, 0.8–1.6), P ¼ 0.47]. In univariate analysis, nsVT patients treated with ﬁbrinolysis, had signiﬁcantly
higher mortality when compared with those without nsVT (P, 0.001). However, after adjustment for
other relevant prespeciﬁed risk factors, the association between nsVTand mortality did not remain stat-
istically signiﬁcant. In patients treated with primary angioplasty, nsVTwas not associated with mortality
in either univariate or multivariate analyses.
Conclusion Immediate revascularization with primary angioplasty for STEMI does not affect the sub-
sequent prevalence of nsVT when compared with ﬁbrinolysis. After adjustment for other relevant risk
factors, the prognostic value of nsVT detected early after STEMI is limited, regardless of the chosen
reperfusion strategy.
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Introduction
Episodes of non-sustained ventricular tachycardia (nsVT)
were established as a prognostic marker after acute myocar-
dial infarction (AMI) in the pre-ﬁbrinolytic era,1 and is
generally considered a marker of arrhythmic propensity.
However, following the advent of ﬁbrinolysis, the prognostic
value of this marker has been questioned.2–4 In a study from
the Italian Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarto Miocardico (the GISSI-2 study), where Holter
monitoring was performed in 8676 patients with a recent
ﬁbrinolytic-treated AMI, nsVT was not an independent pre-
dictor of neither arrhythmic nor all-cause mortality,3 and
the results of more recent studies have been conﬂicting.4–8
However, using the presence of nsVT on Holter monitoring,
left ventricular (LV) ejection fraction (EF) (LVEF) 35%,
and inducible, non-suppressible ventricular tachyarrhythmia
on electrophysiological study as the main selection criteria,
the Multicenter Automatic Deﬁbrillator Implantation Trial
(MADIT) demonstrated improved survival with an implanta-
ble cardioverter-deﬁbrillator (ICD) strategy as opposed to
conventional antiarrhythmic therapy in the survivors of
AMI.9 As a result, Holter monitoring is by many considered
an important clinical examination in AMI survivors with an
LVEF 35%. The clinical implications of nsVT in patients
with an LVEF .35% remain more disputed, although recent
data have suggested that several Holter-derived markers
of arrhythmic propensity, including nsVT, are of independent
prognostic value in such patients.10
Over the last decade, primary angioplasty has evolved as a
superior alternative to ﬁbrinolysis for the treatment of
acute ST-segment elevation myocardial infarction (STEMI),
as a greater reduction of major cardiovascular events is
achieved with this approach.11,12 Therefore, primary angio-
plasty has in many centres become the treatment of choice
for patients with acute STEMI. The impact of primary angio-
plasty on the subsequent prevalence and clinical signiﬁ-
cance of nsVT is presently unknown. Although some recent
studies have included patients treated with primary
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angioplasty,4,10,13 none of these were designed for a direct
comparison with ﬁbrinolysis. Our primary objective was
therefore to compare the prevalence and prognostic impli-
cations of nsVT in patients with acute STEMI, randomized
to treatment with either primary angioplasty or ﬁbrinolysis
in the Danish Multicenter Randomized Study on Fibrinolytic
Therapy vs. Acute Coronary Angioplasty in Acute Myocardial
Infarction (DANAMI-2).
Methods
The design and results of the DANAMI-2 main study has previously
been reported.14,15 DANAMI-2 is a Danish multi-centre study with
29 participating centres (24 referral; ﬁve invasive). The main
inclusion criteria were an age of 18 years or more, symptoms
characteristic of AMI for at least 30 min but ,12 h, and cumulative
ST-segment elevation of at least 4 mm in at least two contiguous
leads. Patients with contraindications to either ﬁbrinolysis or
primary angioplasty and patients with left bundle branch block on
ECG were excluded. Patients judged to be at high risk during
transportation because of cardiogenic shock or severe heart
failure (a sustained systolic blood pressure 65 mmHg), persistent
life-threatening arrhythmias, or a need for mechanical ventilation
were also excluded. Patients randomized to primary angioplasty at
a non-invasive referral centre, were immediately transferred to
the regional invasive centre. If patients were randomized to ﬁbrino-
lysis they remained at the invasive or referral centre.
The study was conducted in accordance with the Declaration of
Helsinki, and was approved by the National Ethics Committee of
Denmark. All eligible patients provided written informed consent.
Holter monitoring
Twenty four-hour Holter monitoring was performed by the rando-
mizing centre and initiated on the day of discharge. Treatment
with beta-blockers and other antiarrhythmic therapy was not dis-
continued during monitoring. Detailed written information was sup-
plied, and teaching of nurses/technicians was available upon
request. Routinely, two bipolar leads were recorded (CM5 and
CM3), but the use of alternative leads was allowed in order to
ensure technically adequate recordings. Calibrated high quality
tapes (TDK, C-90) were used. Recordings were submitted unana-
lysed to a core-laboratory (Department of Medical Research,
Funen Hospital, Denmark) and analysed using a semi-automated
program (Reynolds Pathﬁnder 700, Del Mar Reynolds Medical Ltd,
UK). The recordings were reviewed by an experienced observer,
blinded to all clinical information of the patient. An episode of
nsVT was deﬁned by at least three consecutive ventricular prema-
ture beats (VPBs) with an RR interval 600 ms. In addition, the
total number of VPBs was assessed and indexed for recording
time. Frequent VPBs, another marker of arrhythmic propensity,
was deﬁned using a prespeciﬁed cut-point of 10 VPBs/h, as
frequently used in previous studies.3,16
Assessment of LV systolic function
Echocardiography was performed at the time of discharge from the
randomizing centre using video recording and submitted to a core-
laboratory (Glostrup University Hospital, Denmark) where LV systolic
function was assessed using a previously validated wall motion index
(WMI) scoring system.17,18 WMI was estimated semi-quantitatively
using a 16 segment-score and assessed using the parasternal long-
and short-axis views and apical views. WMI score was visually
assessed accounting for the contribution of each LV segment to sys-
tolic reduction of LV volume; a score of 2 was assigned to each
segment with normal thickening; scores of 1.5, 1.0, and 0.5 were
assigned to mild, moderate, and severe hypokinetic segments,
respectively; 0 was assigned to akinetic and 21 to dyskinetic
segments. WMI was calculated by adding the score of each
segment and dividing by the number of segments. From the result-
ing WMI score, LVEF was estimated using a previously validated
method.18 All echocardiograms were blindly read by two established
echocardiographic readers.
Coronary angiograms
Coronary angiograms obtained during the primary revascularization
procedure in patients randomized to primary angioplasty were eval-
uated by an independent core laboratory (Cardialysis, Rotterdam,
the Netherlands) where the number of diseased vessels (i.e.
vessels with 50% stenosis) and post-angioplasty coronary ﬂow
grade was assessed according to the Thrombolysis in Myocardial
Infarction (TIMI) classiﬁcation.19
Follow-up and endpoints
Physicians responsible for the follow-up and treatment of patients
were kept unaware of the results of Holter monitoring throughout
the study. Patients were followed in an outpatient clinic at the ran-
domizing centre with a visit 30 days after discharge, and thereafter
once yearly for 3 years. Survival status of all patients was obtained
from the Danish Civil Registration System, where all deaths in the
country are recorded within 2 weeks. This was done 3 years after
inclusion of the last patient, yielding a follow-up period ranging
from 3 to 7 years resulting in 4519 patient-years of follow-up.
Causes of death were classiﬁed by the DANAMI-2 main study end-
point committee based on medical records and information avail-
able from death certiﬁcates. The primary endpoint of this study
was all-cause mortality. A secondary endpoint was arrhythmic mor-
bidity during the ﬁrst 3 years of follow-up. Arrhythmic morbidity
was deﬁned as arrhythmic death, resuscitated ventricular ﬁbrilla-
tion, or documented episodes of sustained ventricular tachycardia
(at a heart rate.120 b.p.m., and lasting for.30 s). Death was con-
sidered arrhythmic if it occurred suddenly or within 1 h of symp-
toms, in a clinically stable patient without a history of progressive
heart failure or angina pectoris. Unwitnessed death, including
death during sleep, was also considered arrhythmic if no other
cause of death was suspected from preceding symptoms or was
documented by autopsy. The ﬁxed follow-up time for the secondary
endpoint was chosen because data regarding non-fatal endpoints
were not available after the end of the clinical follow-up period
of 3 years.
Statistics
Analyses were conducted with STATA/SE 9.2 (StataCorp LP, TX, USA).
Results were analysed according to the intention-to-treat principle.
Continuous variables are reported as mean+ SD and prevalence as
percentage. Comparison of patient characteristics and the preva-
lence of predeﬁned Holter measurements was performed with
Student’s t-test (unpaired, two-tailed) for continuous variables,
whereas categorical variables were compared using a x2 test or
Fisher’s exact test when appropriate. Interaction between random-
ized treatment and differences in clinical characteristics associated
with nsVT, was tested using logistic regression. Hazard ratios were
estimated using Cox proportionate hazards regression analysis.
The prespeciﬁed Holter variables were split into separate variables
for each of the two treatment groups and adjusted for the following
variables, chosen prior to the inspection of data: age, sex, diabetes,
previous MI, anterior index MI, and LVEF. Proportionality of hazards
was tested graphically based on visual inspection of log–log survival
curves, and by performing a formal test of proportionality based on
Schoenfeld residuals for each variable in the model. Furthermore,
for age and LVEF, linearity of hazards was tested by adding
squared values of the variables to the model. Because these ana-
lyses indicated a time-dependent effect of LVEF on mortality, we
used a ﬁnal Cox model stratiﬁed by LVEF dichotomized at 35%
(reported multivariable coefﬁcients equal across strata but with
408 D. E. Høfsten et al.
 by guest on January 9, 2017
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
baseline hazard unique to each stratum of LVEF). Assumptions of
proportionality and linearity of hazards was met for all other
included variables. A two-sided value of P, 0.05 was considered
statistically signiﬁcant in all analyses.
Results
Patient characteristics
A study ﬂowchart is shown in Figure 1. From a total of 1462
patients discharged alive from index infarction, Holter
monitoring was performed in 1159 patients at a median of
6 days (IQR: 5–8 days) after randomization. Patients in
whom Holter recording was not performed (n ¼ 303) were
signiﬁcantly older (64.7+ 13.8 vs. 61.7+ 11.8 years;
P, 0.001) and experienced a signiﬁcantly higher mortality
rate during follow-up (HR, 2.1; 95% CI, 1.4–3.0). The
decision of not to perform a Holter recording was made at
the discretion of the treating physician in all cases. In
addition, 142 recordings were excluded, due to technically
inadequate quality of the recording, thus leaving a total of
1017 recordings available for the study. Baseline character-
istics for these patients are summarized in Table 1.
Prevalence of nsVT and VPBs
In the ﬁbrinolysis-treated group, nsVTwas found in 44 (8.8%)
patients when compared with 42 (8.1%) in the angioplasty
group (P ¼ 0.71). If applying a more restrictive deﬁnition
of nsVT, including only episodes with an RR interval
,500 ms (.120 b.p.m.), the prevalence of nsVT was 7.4%
in the ﬁbrinolysis group, and 6.2% in the angioplasty group
(P ¼ 0.45).
AVPB frequency 10/h was found in 78 (15.6%) patients in
the ﬁbrinolysis group, when compared with 62 (12.0%) in the
angioplasty group (P ¼ 0.10).
Echocardiography was performed in 979 (96.3%) patients
at a median of 5 days (IQR: 4–7 days) after randomization,
and showed an LVEF 35% in 178 (18.2%) patients (ﬁbrinoly-
sis: 18.8%; primary angioplasty 17.6%; P ¼ 0.61). The combi-
nation of LVEF 35% and at least one episode of nsVT was
present in 12 (2.5%) patients treated with ﬁbrinolysis, and
in 11 (2.2%) patients treated with primary angioplasty
(P ¼ 0.75).
Clinical characteristics by presence or
absence of nsVT
Patients with nsVT in the two treatment groups are shown in
Table 2. Mean LVEF was lower in patients with nsVT,
suggesting an association between severity of myocardial
damage and the risk of developing nsVT. In addition, age
was higher among patients with nsVT, although this associ-
ation was less pronounced among patients in the angioplasty
group.
The prevalence of other characteristics such as male sex,
diabetes, anterior index infarction, and mean heart rate
during Holter recording, were not signiﬁcantly different in
patients with nsVT when compared with the remaining
study population. In the angioplasty group, where angio-
graphic data were available, the prevalence of nsVT was
unrelated to the number of diseased vessels and post-
angioplasty TIMI ﬂow grade in the assumed culprit lesion.
Prognostic implications of nsVT
During a median follow-up period of 4.3 years (IQR: 3.7–5.3
years), 116 patients died [ﬁbrinolysis vs. angioplasty:
HR ¼ 1.1 (95% CI 0.8–1.6), P ¼ 0.47]. In a univariate model,
nsVT was associated with increased mortality in the total
study population [HR ¼ 2.1 (95% CI 1.3–3.5), P ¼ 0.003,
Figure 2A]. When the two treatment groups were analysed
separately, nsVTwas associated with mortality in the ﬁbrino-
lysis group [HR ¼ 2.9 (95% CI 1.5–5.5), P ¼ 0.001, Figure 2B]
but not in the group treated with primary angioplasty
[HR ¼ 1.4 (95% CI 0.6–3.3), P ¼ 0.42, Figure 2C]. However,
interaction between treatment group and the
prognostic value of nsVT was not statistically signiﬁcant
(Pinteraction ¼ 0.17).
The secondary endpoint of arrhythmic morbidity was
observed in 23 cases (ﬁbrinolysis: n ¼ 14; angioplasty:
n ¼ 9; log-rank P ¼ 0.26). Arrhythmic morbidity was seen
more frequently among patients with nsVT [HR ¼ 3.1 (95%
CI 1.2–8.4), P ¼ 0.02, Figure 4A]. The absolute number of
arrhythmic events in patients with nsVT was however very
low (ﬁbrinolysis: n ¼ 2; angioplasty: n ¼ 3), and the
additional risk of nsVT was not signiﬁcantly different in the
two treatment groups (Pinteraction ¼ 0.28).
During the ﬁrst 3 years of follow-up, seven patients were
treated with an implantable cardioverter-deﬁbrillator. Of
these, nsVT had been present on Holter monitoring in one
patient in the angioplasty group, and none in the ﬁbrinolysis
group.
Prognostic implications of frequent VPBs
A VPB frequency 10/h was associated with increased mor-
tality in the total study population [HR ¼ 2.6 (95% CI
1.8–3.9), P, 0.001, Figure 3A]. There was no signiﬁcant
interaction between randomized treatment and prognostic
importance of frequent VPBs (Pinteraction ¼ 0.28). The sec-
ondary endpoint of arrhythmic morbidity also occurred
more frequently in patients with 10 VPBs/h [HR ¼ 2.8
(95% CI 1.1–6.8), P ¼ 0.02, Figure 4B].
Multivariable analysis
Cox proportionate hazards regression analysis was per-
formed using age, sex, diabetes, previous myocardial infarc-
tion, anterior index infarction, beta-blocker treatment at
discharge, nsVT, and 10 VPBs/h as covariates, and stratify-
ing by LVEF 35%. Age was entered as a continuous variable.
In this model, after adjustment for other signiﬁcant risk
factors, neither nsVT nor frequent VPBs were independently
associated with increased mortality in either of the two
treatment groups (Table 3). Given the few cases of arrhyth-
mic morbidity in patients with nsVT, multivariable analysis
was not performed for this secondary endpoint.
Discussion
This is the ﬁrst randomized study to compare the prevalence
and prognostic signiﬁcance of ventricular arrhythmias after
primary angioplasty and ﬁbrinolysis, respectively. Primary
angioplasty did not decrease incident nsVT when compared
with ﬁbrinolysis treatment. While, unlike in the angioplasty
group, a univariate association between nsVT and all-cause
mortalitywasobserved in theﬁbrinolysis group, inmultivariable
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regression analysis, nsVT did not independently predict mor-
tality in either of the two treatment groups, and there was no
statistical evidence of interaction between randomized treat-
ment, and the prognostic implications of nsVT. The hypothesis
of less ventricular arrhythmia in patients treated with primary
angioplasty due to faster and more complete revascularization
of the infarct related area was not substantiated in our study.
Our ﬁndings are similar to a previous study of 400 consecutive
STEMI patients all treated with primary angioplasty, with a 10%
rate of nsVT,13 as well as rates of 6.8–9.0% in previous studies,
including ﬁbrinolysis-treated patients.3,4 Survival of more criti-
cally ill patients with AMI made possible by primary angioplasty
has been suggested as an explanation for the similar prevalence
of ventricular arrhythmias observed among patients treated
with primary angioplasty when compared with ﬁbrinolysis.13
This was not evident in our study, as other risk factors such as
age and impaired LV systolic function were equally distributed
among the two treatment groups. In accordance with this
Figure 1 Study ﬂowchart.
Table 1 Baseline characteristics of angioplasty and ﬁbrinolysis-treated patients (n ¼ 1017)
Fibrinolysis (n ¼ 501) Primary angioplasty (n ¼ 516) P
Age, years (mean+ SD) 61.7+ 12.0 61.6+ 11.5 0.88
Male sex, n (%) 378 (75.5) 389 (75.4) 0.98
Treated hypertension, n (%) 104 (20.8) 100 (19.4) 0.58
Previous MI, n (%) 52 (10.4) 54 (10.5) 0.96
Diabetes, n (%) 31 (6.2) 34 (6.6) 0.79
Smokinga
Never, n (%) 91 (18.2) 87 (16.9) 0.59
Former, n (%) 105 (21.0) 113 (21.9) 0.71
Current, n (%) 300 (59.9) 314 (60.9) 0.75
Anterior index MI, n (%) 250 (49.9) 262 (50.8) 0.78
Heart rate, b.p.m. (mean+ SD) 67.0+ 10.7 68.0+ 11.7 0.15
LVEF, % (mean+ SD) 46.2+ 11.3 46.7+ 11.1 0.48
LVEF  35%, n (%)b 90 (18.8) 88 (17.6) 0.61
Angiographic features
No stenotic vessels, n (%) 19 (3.8) –
Single-vessel disease, n (%) 153 (30.8) –
Double-vessel disease, n (%) 159 (32.0) –
Triple-vessel disease, n (%) 166 (33.4) –
Medication at discharge
Aspirin, n (%) 487 (97.2) 498 (96.5) 0.53
Beta-blockers, n (%) 436 (87.0) 456 (89.2) 0.30
Other antiarrhythmics, n (%)c 15 (3.0) 19 (3.7) 0.54
Calcium antagonists, n (%) 39 (7.8) 30 (5.8) 0.21
Digoxin, n (%) 30 (6.0) 19 (3.7) 0.09
ACE-inhibitors, n (%) 188 (37.5) 168 (32.6) 0.10
Statins, n (%) 257 (51.3) 256 (49.6) 0.59
aSmoking cessation within last 6 months was considered current smoking.
bPercentages are relative to the number of patients where LVEF was available (n ¼ 979).
cOther antiarrhythmics used were amiodarone (n ¼ 18), sotalol (n ¼ 14), and propafenone (n ¼ 2).
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Table 2 Clinical characteristics by presence or absence of non-sustained ventricular tachycardia
Fibrinolysis Primary angioplasty Interaction
nsVT present
(n ¼ 44)
nsVT absent
(n ¼ 457)
P nsVT present
(n ¼ 42)
nsVT absent
(n ¼ 474)
P PInteraction
Age, years (mean+ SD) 69.0+ 12.1 61.0+ 11.7 ,0.0001 64.6+ 11.9 61.4+ 11.4 0.08 0.11
Male sex, n (%) 38 (86.4) 340 (74.4) 0.08 33 (78.6) 356 (75.1) 0.62 0.33
Diabetes, n (%) 2 (4.5) 29 (6.3) 0.64 3 (7.1) 31 (6.5) 0.88 0.65
Anterior index MI, n (%) 24 (54.5) 226 (49.5) 0.52 22 (52.4) 240 (50.6) 0.83 0.77
LVEF (mean+ SD), % 43.4+ 11.7 46.5+ 11.3 0.09 42.4+ 12.7 47.1+ 10.9 0.01 0.52
Heart rate, b.p.m. (mean+ SD) 69.6+ 12.4 66.7+ 10.5 0.09 67.1+ 10.3 68.1+ 11.7 0.61 0.12
Diseased vessels, n (%) 0.75 –
Single 11 (26.8) 142 (32.5) – –
Double 15 (36.6) 144 (33.0) – –
Triple 15 (36.6) 151 (34.6) – –
TIMI ﬂow grade 3, n (%) 31 (81.6) 352 (83.6) 0.75 –
N
on-sustained
V
T
after
coronary
revascularization
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clinical practice, the risk proﬁle of patients selected for primary
angioplastymay differ from that of patients selected for ﬁbrino-
lysis, and accordingly, so may the subsequent prevalence of
several risk factors including markers of arrhythmic propensity.
Prognostic implications of nsVT
The GISSI-2 Holter substudy is probably the largest post-
infarction study investigating the prognostic implications
of nsVT detected early after STEMI. Similar to our study,
Holter monitoring of 8676 ﬁbrinolysis-treated patients,
showed a univariate association between nsVTand mortality,
which did not remain after adjustment for relevant clinical
risk factors3 and this emphasizes the correlation between
nsVT and other risk factors. Also similar to our study, a
recent study of 400 STEMI primary angioplasty-treated
patients showed that nsVT did not predict mortality in
either univariate or multivariate analyses.13 It is important
to note that our study did show a signiﬁcant association
between nsVT and arrhythmic morbidity. However, the end-
point event-rate was much lower than anticipated, and
multivariable analysis was therefore not feasible. Among
the 86 patients with documented nsVT, arrhythmic events
were only observed in ﬁve (5.8%) cases. It is therefore
likely that any statistical association between nsVT and
arrhythmic morbidity could be clinically insigniﬁcant.
Timing of Holter recording
The prevalence and prognostic implications of nsVT have in
previous studies been variable, depending on the timing of
Holter recording. In the present study, recordings were per-
formed on the day of discharge. In the second Danish
Verapamil Infarction Trial (DAVIT II), before the widespread
use of primary angioplasty, serial Holter recordings were
performed at 1 week, 1 month, and 16 months following
AMI. In that study, nsVT was an independent predictor of
outcome when detected late (16 months) but not early
(1 week and 1 month) after AMI.8 In the MADIT trial, more
than 75% of all patients were included later than 6 months
after their last AMI, and patients with episodes of nsVT
documented during admission for AMI were not eligible.9
Therefore, very few of the qualifying episodes of nsVT in
the MADIT trial, were recorded as early as in the present
study. One could speculate that markers of arrhythmic
propensity detected early after AMI, in some patients are
attributable to benign and potentially reversible electro-
physiological instability and ‘myocardial stunning’, which
may resolve over the following months, depending on the
degree of reperfusion and ventricular myocardial remodel-
ling. It is therefore also possible, that the rate of nsVT
would differ between the two treatment groups, if Holter
monitoring was performed several months after AMI.
However, in another study nsVT detected within the very
ﬁrst days of admission for AMI was a signiﬁcant risk factor
for subsequent mortality.6 Studies assessing the ideal time
for detecting clinically relevant markers of arrhythmic pro-
pensity after primary angioplasty are therefore warranted.
Study limitations
The timing of Holter recordingmay in somepart have affected
our study results. We chose to perform Holter monitoring on
the day of discharge, causing some variation in the number
of days from index infarction. However, this was chosen in
order to obtain more homogeneity in the clinical state, and
degree of physical activity of patients at the time of record-
ing, than would have been found if a ﬁxed time-point had
been chosen. Another limitation of the study relates to the
Figure 3 Cumulative survival probability for patients with 10 VPBs/h,
compared to those with ,10 VPBs/h in the total study population (A) and
in the two treatment groups, respectively (B,C).
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general risk proﬁle of the investigated cohort. Because of the
exclusion criteria of the DANAMI-2 study, and the fact that
Holtermonitoringwas performed at discharge, thus excluding
all patients who died before the Holter was performed, our
cohort were generally a low-risk population. In particular,
the rate of arrhythmic events was surprisingly low in this
study. Holter monitoring was, by choice of the treating phys-
ician, not performed in 303 patients. These patients were
older, and experienced higher mortality rates than the inves-
tigated cohort. It is therefore possible that the prevalence
and prognostic implications of the investigated variables
differ from what would be found in an unselected population
with STEMI. On the other hand, this study lends additional
support to what was also observed in the Prevention of
Events with ACE inhibition (PEACE) trial;20 the fact that the
treatment of STEMI is now so effective that once patients
are discharged, they are at quite low cardiovascular risk
making at least some risk predictors superﬂuities.
Conclusions
Our study does not suggest that rapid revascularization using
primary angioplasty reduces the subsequent prevalence of
nsVT after STEMI when compared with ﬁbrinolysis.
Furthermore, the prognostic value of nsVT in our study
was limited, and did not appear to be affected by the
choice of reperfusion strategy.
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